Related Experiment Video
Updated: Jul 8, 2026
Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
Published on: September 9, 2011
Human γδ T Cell Function Is Impaired Upon Mevalonate Pathway Inhibition
Tsz Kin Suen1, Burcu Al1, Thomas Ulas2,3,4
1Immunology and Metabolism, Life and Medical Sciences Institute, University of Bonn, Bonn, Germany.
Abstract:
Vδ2 T cells, a predominant human peripheral γδ T cell population, are a promising candidate for the development of immunotherapies against cancer and infected cells. Aminobisphosphonate drugs, such as zoledronate, are commonly used to expand Vδ2 T cells. Yet, such in vitro generated cells have limited efficacy in the clinic. We found that despite inducing excessive proliferation of Vδ2 T cells, zoledronate impaired their effector function and caused the upregulation of the inhibitory receptor TIM3. This effect was due to the inhibition of mevalonate metabolism and dysregulation of downstream biological processes such as protein prenylation and intracellular signalling. In vitro and in vivo inhibition of mevalonate metabolism with zoledronate, statins, and 6-fluoromevalonate, as well as genetic deficiency of the mevalonate kinase, all resulted in compromised cytokine and cytotoxic molecule production by Vδ2 T cells. Impaired Vδ2 T cell function was accompanied by transcriptome and kinome changes. Our findings reveal the importance of mevalonate metabolism for the proper functioning of Vδ2 T cells. This observation provides important considerations for improving their therapeutic use and has repercussions for patients with statin or aminobisphosphonate treatments.
Insights
Zoledronate expands Vδ2 T cells but impairs their function by inhibiting mevalonate metabolism. This finding is crucial for improving Vδ2 T cell immunotherapies and understanding statin/aminobisphosphonate treatment effects.
Area of Science:
- Immunology
- Cell Biology
- Biochemistry
Background:
- Vδ2 T cells are key players in immunotherapy for cancer and infections.
- Aminobisphosphonates like zoledronate are used to expand Vδ2 T cells in vitro.
- Current in vitro generated Vδ2 T cells show limited clinical efficacy.
Purpose of the Study:
- To investigate the impact of zoledronate on Vδ2 T cell effector function.
- To elucidate the molecular mechanisms underlying zoledronate-induced Vδ2 T cell dysfunction.
- To explore the role of mevalonate metabolism in Vδ2 T cell function.
Main Methods:
- In vitro and in vivo experiments using zoledronate, statins, and 6-fluoromevalonate.
- Assessment of Vδ2 T cell proliferation, effector function, and TIM3 expression.
- Analysis of mevalonate metabolism, protein prenylation, and intracellular signaling.
- Transcriptome and kinome profiling.
Main Results:
- Zoledronate induced excessive Vδ2 T cell proliferation but impaired effector function and upregulated TIM3.
- Inhibition of mevalonate metabolism by zoledronate, statins, or genetic deficiency compromised Vδ2 T cell cytokine and cytotoxic molecule production.
- Disruption of mevalonate metabolism led to altered transcriptome and kinome profiles.
- Impaired protein prenylation and intracellular signaling were observed.
Conclusions:
- Mevalonate metabolism is essential for optimal Vδ2 T cell function.
- Zoledronate's inhibition of mevalonate metabolism underlies Vδ2 T cell dysfunction.
- Findings necessitate re-evaluation of Vδ2 T cell expansion protocols and have implications for patients on statin or aminobisphosphonate therapy.
